^
Association details:
| Biomarker: | RICTOR amplification |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | sapanisertib (CB-228) (mTORC1 inhibitor, mTORC2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
RICTOR amplification defines a novel subset of lung cancer patients who may benefit from treatment with mTOR1/2 inhibitors
Excerpt:
A young male never-smoker was diagnosed with lung adenocarcinoma in 5/2010 at the age of 18...Analysis estimated focal RICTOR amplification of 7 copies as the sole tumor-specific genomic alteration among the cancer-related genes examined...Given activation of both mTORC1 and mTORC2 signaling, the index patient was treated on a phase I clinical trial with a dual mTOR1/2 inhibitor, CC223 and had stable disease for 12 months....He was started again with a dual mTOR1/2 inhibitor, MLN0128 on a phase I trial on 2/2015. Restaging imaging with CT chest/abdomen after 6 cycles revealed stable disease and he continues to receive treatment with this agent.
DOI:
10.1158/2159-8290.CD-14-0971
